NEOGENOMICS INC (NEO) Stock Fundamental Analysis
NASDAQ:NEO - US64049M2098 - Common Stock
8.765 USD
+1.56 (+21.57%)
Taking everything into account, NEO scores 3 out of 10 in our fundamental rating. NEO was compared to 101 industry peers in the Health Care Providers & Services industry. NEO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEO is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year NEO was profitable.
NEO had a positive operating cash flow in the past year.
NEO had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NEO reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -7.46%, NEO is not doing good in the industry: 73.27% of the companies in the same industry are doing better.
With a Return On Equity value of -12.18%, NEO is not doing good in the industry: 60.40% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.46% | ||
| ROE | -12.18% | ||
| ROIC | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 43.91%, NEO is in the better half of the industry, outperforming 73.27% of the companies in the same industry.
In the last couple of years the Gross Margin of NEO has declined.
NEO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
2. Health
2.1 Basic Checks
NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NEO has more shares outstanding
The number of shares outstanding for NEO has been increased compared to 5 years ago.
Compared to 1 year ago, NEO has a worse debt to assets ratio.
2.2 Solvency
NEO has an Altman-Z score of 1.16. This is a bad value and indicates that NEO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.16, NEO is not doing good in the industry: 65.35% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.40 indicates that NEO is not too dependend on debt financing.
NEO's Debt to Equity ratio of 0.40 is fine compared to the rest of the industry. NEO outperforms 64.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.16 |
ROIC/WACCN/A
WACC6.77%
2.3 Liquidity
NEO has a Current Ratio of 3.92. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO has a better Current ratio (3.92) than 89.11% of its industry peers.
A Quick Ratio of 3.58 indicates that NEO has no problem at all paying its short term obligations.
NEO has a better Quick ratio (3.58) than 89.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.92 | ||
| Quick Ratio | 3.58 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 200.00% over the past year.
NEO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -20.25% yearly.
NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.69%.
NEO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.07% yearly.
EPS 1Y (TTM)200%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%0%
Revenue 1Y (TTM)9.69%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%10.23%
3.2 Future
The Earnings Per Share is expected to grow by 52.63% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.52% on average over the next years. This is quite good.
EPS Next Y-8.02%
EPS Next 2Y34.81%
EPS Next 3Y58.22%
EPS Next 5Y52.63%
Revenue Next Year9.08%
Revenue Next 2Y9.59%
Revenue Next 3Y9.54%
Revenue Next 5Y8.52%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 73.04, NEO can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as NEO.
Compared to an average S&P500 Price/Earnings ratio of 27.17, NEO is valued quite expensively.
With a Price/Forward Earnings ratio of 48.23, NEO can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NEO is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.78, NEO is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 73.04 | ||
| Fwd PE | 48.23 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NEO's earnings are expected to grow with 58.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.81%
EPS Next 3Y58.22%
5. Dividend
5.1 Amount
No dividends for NEO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NEO (8/29/2025, 3:36:06 PM)
8.765
+1.56 (+21.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.94%
Inst Owner Change1.56%
Ins Owners1.08%
Ins Owner Change2.92%
Market Cap1.13B
Analysts71.58
Price Target8.62 (-1.65%)
Short Float %3.95%
Short Ratio2.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)65.8%
Min EPS beat(2)31.6%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)116.23%
Min EPS beat(4)31.6%
Max EPS beat(4)298.27%
EPS beat(8)8
Avg EPS beat(8)214.41%
EPS beat(12)12
Avg EPS beat(12)159.12%
EPS beat(16)16
Avg EPS beat(16)122.94%
Revenue beat(2)0
Avg Revenue beat(2)-2.21%
Min Revenue beat(2)-2.68%
Max Revenue beat(2)-1.73%
Revenue beat(4)0
Avg Revenue beat(4)-1.65%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)-0.51%
Revenue beat(8)4
Avg Revenue beat(8)0.55%
Revenue beat(12)8
Avg Revenue beat(12)2.36%
Revenue beat(16)9
Avg Revenue beat(16)1.45%
PT rev (1m)-22.82%
PT rev (3m)-22.26%
EPS NQ rev (1m)-56.85%
EPS NQ rev (3m)-60.45%
EPS NY rev (1m)-42.63%
EPS NY rev (3m)-49.05%
Revenue NQ rev (1m)-4.46%
Revenue NQ rev (3m)-2.54%
Revenue NY rev (1m)-3.14%
Revenue NY rev (3m)-3.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 73.04 | ||
| Fwd PE | 48.23 | ||
| P/S | 1.64 | ||
| P/FCF | N/A | ||
| P/OCF | 80.59 | ||
| P/B | 1.33 | ||
| P/tB | 40.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.12
EY1.37%
EPS(NY)0.18
Fwd EY2.07%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.11
OCFY1.24%
SpS5.34
BVpS6.61
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.46% | ||
| ROE | -12.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.91% | ||
| FCFM | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 46.68% | ||
| Cap/Sales | 4.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.92 | ||
| Quick Ratio | 3.58 | ||
| Altman-Z | 1.16 |
F-Score5
WACC6.77%
ROIC/WACCN/A
Cap/Depr(3y)46.9%
Cap/Depr(5y)68.48%
Cap/Sales(3y)5.71%
Cap/Sales(5y)7.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)200%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%0%
EPS Next Y-8.02%
EPS Next 2Y34.81%
EPS Next 3Y58.22%
EPS Next 5Y52.63%
Revenue 1Y (TTM)9.69%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%10.23%
Revenue Next Year9.08%
Revenue Next 2Y9.59%
Revenue Next 3Y9.54%
Revenue Next 5Y8.52%
EBIT growth 1Y-4.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.72%
EBIT Next 3Y41.96%
EBIT Next 5Y30.18%
FCF growth 1Y70.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y141.09%
OCF growth 3YN/A
OCF growth 5Y-21.37%